Board forward stakeholder for closely unlock of future new our the Thank to conference you, role Doug. Good excited look and value. leadership thank team with Semler. being everyone, afternoon, my working I our senior of today's for to and call. I'm you part in
in the Eric Chang management. allocation, that our capital investment bring pleased expertise corporate second deep are have joined Semler Board strategic Will and governance, XXXX. of They planning quarter in both We and
and he Officer. Chief ask with Rosenberg bring has XX after and has Board Semler, years decided to retired order to agreed. on Semler, Doug Marketing continuity as CEO direction permanent stay in Also to the to Dennis Furthermore, his has
However, We his he and contributions a me to our with for him and Dennis happy Relations wish effort. continue valuable assist fulfilling will Investor retirement. thank
be I'll financial providing quarter and discussing results, developments. updates market our of corporate XXXX an second recent Today, overview presenting
Following I be questions you our recognize to the team have. as the to clinical to of to benefits my for of address second announce ongoing available quarter. support technology. remarks, of excited work value Doug a the This record continue is and will as to our achievement any the may and who I'm hard results testament well customers our
By enabling treatments early also this proactive diagnosis at and expenditure. lowers PAD to and preventative approach initiate saves are heart of healthcare providers lives, stage. We we believe early interventions healthcare only both an but that not dysfunction, empowering
look future, healthcare outcomes patients, we As technology substantial where our role to while plays landscape the we a shaping pivotal economic healthier for envision the benefits. delivering in
underscore the PAD. implementation promising last asymptomatic in an preventative customers year independently are that QuantaFlo sales continued test were identifying large conducted These For studies to by an now, impact. our QuantaFlo XXXX quarter peer-reviewed enabling results. patients, XX% new revenue that We compared PAD specifics million, published existing for QX Total customers $XX.X believe was two to and by second XXXX, of studies having importance of results the of quarter the measures. increase to of the second in of of driven
were Variable an from interest delegated as medical customers, million, were $X.X XX% as year-over-year. Fixed retail an such our increase as saw We million, new well and and XX% products customers fee revenues fee existing other hospitals, major in revenues year-over-year. increase groups. of $X.X pharmaceutical of continued chains
other market. believe and test $XXX,XXX, customers, for is QuantaFlo our see fee sales we assessment demand examinations. equipment variable to Because PAD in to of strong home risk using Equipment fee of customers XXX% an are it were continue during per revenues sign majority the a increase year-over-year. from the strength We in-home of
quarter their our of million, including related which two second XX% revenues, customers, expenses were and cost QX XX% XXXX, comprised of the affiliates, Operating in XX% of includes of largest quarterly In increase an XXXX, $XX.X revenues. year-over-year.
XXXX. of to to expenses As decreased percent compared a operating revenues, XX% XX% in
to diluted $X.X Pre-tax Operating professional $X.X net share, due per inflation expenses primarily headcount, $X.XX increased of XX% fees. XX% million, Net million, of increase an or income year-over-year. an basic income year-over-year. and $X.XX was million wage increased per was and or increased X.X increase share
purchased our from shares During acquire outstanding we the to XX,XXX CEO cost at of a stock warrants quarter, million. of common $X.X
stock million cash $XX Board authorized cash, XX, short-term have XXXX We $XX.X equivalents repurchase million. investments remaining under at had the of program. June and We
reduce while September As by of XXXX, quarter streamline XXX first This employee plan service strategic approximately by of the customers. recently employees efficiency, is seeks be still XXXX. a compared the XX, our end XXX drive and providing proactive high XX, June quality to meant plan to headcount XX% was headcount to at announced operational to XXXX. operations We and to
fourth paid will expected in $X.X We which range We costs during termination are by in December a the operating currently we million to one-time will of realized December expenses ended reduction incur of quarterly approximately result which expected to benefits, this $X XXX,XXX XX, consisting anticipate quarter are severance to the be XXXX. million, of XX, in estimate XXX,XXX that to be XXXX.
new show particularly our the QuantaFlo, objective company's is may This promise tremendous customer To our Our maintain to prove focusing exciting and in enhance this, revenue believe that future. base reinvesting potential PAD the customers both primary achieve opportunities and steadfast, of remains growth our for broadening HD. and are we profitability. we and for on to current in emerging opportunities,
and maintaining innovation continuing to of we services cutting-edge we're existing to for strive a at Upgrading deliver the our to data and investments Furthermore, customers. priority products us and in stay research solutions development. is committed forefront as to our
a correlation of Journal of of to is transthoracic heart Preventative our diagnosis paper diagnose product echo, the HD paper The our which value A a a the on we in in results to clinical echocardiography, press a release aid heart R&D a in to Medicine unveiled internal demonstrated or of published is using of statistically failure. significant standard dysfunction, efforts. available our gold Last year, P March XXXX. website the less X.XX link than with X, dated as QuantaFlo
million X with hospitalizations United a million including in of annual and healthcare on the adults in heart broad failure, around five Heart impact a spectrum, the States of at of dysfunction year $XX risk in exceeding care which of age, the encompasses lifetime years failure per affects With U.S. XX X.X heart over an is billion. significant, one cost
have asymptomatic disease. disease, symptomatic Unlike of number a heart heart patients considerable
and they lab, involves making not of ultrasonographer in home a for current trained test. care a tested while it about for reliable, However, or screening an standard because care are a hour, specialized the setting. impractical is It routinely takes echo, not offices primary
Our guideline long-term this with goal them heart health to a effective identifying outcome. equip proven to healthier therapies. cost approach to and medical asymptomatic of means dysfunction optimize encourage could Ultimately, adopt lifestyles directed providers improve healthcare is patients early, enabling
HCC by year's There diagnosis are CPT affected for updates. this codes CMS that were for and not codes echocardiography heart dysfunction reimbursement
HD customers XXXX. second of We discussions in and quarter the are have with all made sizes, in of of QuantaFlo initial installations
signs, take process early is expect showing uptake time. we HD positive the will While market
aim market. our we part will opportunities product growth Board new as initiatives portfolio has in Finally, to seeking support. explore our and we your our further guided to Thank on By our of the partnerships, deep and diversify the offerings interest growth strategy, broaden for company allocation. continuing experience inorganic impact and by your in our that you capital expand
to will your and questions. the Now, lines, happy Rocco, please if address be could you open Doug I
